Modeling the global transmission of antiviral-resistant influenza viruses

Influenza and other Respiratory Viruses

Volumn 7, Issue 1 SUPPL.1, 2013, Pages 58-62

  Chao, Dennis L ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Antiviral agents; Influenza; Mathematical modeling; Neuraminidase inhibitors; Resistance

Indexed keywords

ANTIVIRUS AGENT;

ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; INFLUENZA VIRUS A H1N1; MATHEMATICAL MODEL; NONHUMAN; PRIORITY JOURNAL; PUBLIC HEALTH PROBLEM; SELECTIVE SWEEP; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS STRAIN; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MODELS, BIOLOGICAL; NEURAMINIDASE; OSELTAMIVIR; WORLD HEALTH;

EID: 84871841751     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/irv.12043     Document Type: Article

References (39)

1. Ward P, Small I, Smith J, Suter P, Dutkowski R. Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 2005; 55:i5-i21.
2. Schünemann HJ, Hill SR, Kakad M et al. WHO Rapid Advice Guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect Dis 2007; 7:21-31.
3. Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM. Antiviral agents for the treatment and chemoprophylaxis of influenza - recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1-24.
4. Weinstock DM, Zuccotti G. The evolution of influenza resistance and treatment. JAMA 2009; 301:1066-1069.
5. Moscona A. Global transmission of oseltamivir-resistant influenza. N Engl J Med 2009; 360:953-956.
6. Baranovich T, Saito R, Suzuki Y et al. Emergence of H274Y oseltamivir-resistant A(H1N1) influenza viruses in Japan during the 2008-2009 season. J Clin Virol 2010; 47:23-28.
7. Monto AS, McKimm-Breschkin JL, Macken C et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3years of their use. Antimicrob Agents Chemother 2006; 50:2395-2402.
8. Carr J, Ives J, Kelly L et al. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res 2002; 54:79-88.
9. Herlocher ML, Carr J, Ives J et al. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res 2002; 54:99-111.
10. Bouvier NM, Lowen AC, Palese P. Oseltamivir-resistant influenza A viruses are transmitted efficiently among guinea pigs by direct contact but not by aerosol. J Virol 2008; 82:10052-10058.
11. Ives JA, Carr JA, Mendel DB et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 2002; 55:307-317.
12. Herlocher ML, Truscon R, Elias S et al. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J Infect Dis 2004; 190:1627-1630.
13. Abed Y, Goyette N, Bovin G. A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus. Antivir Ther 2004; 9:577-581.
14. Rameix-Welti MA, Enouf V, Cuvelier F, Jeannin P, van der Werf S. Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir. PLoS Pathog 2008; 4:e1000103. Available from: http://dx.doi.org/10.1371%2Fjournal.ppat.1000103.
15. Baz M, Abed Y, Simon P, Hamelin ME, Boivin G. Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses. J Infect Dis 2010; 201:740-745.
16. Matsuzaki Y, Mizuta K, Aoki Y et al. A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir. Virol J 2010; 7:53.
17. Bloom JD, Gong LI, Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science 2010; 328:1272-1275.
18. Chao DL, Bloom JD, Kochin B, Antia R, Longini IM Jr. The global spread of drug-resistant influenza. J R Soc Interface 2012; 9:648-656.
19. Lofgren E, Fefferman NH, Naumov YN, Gorski J, Naumova EN. Influenza seasonality: underlying causes and modeling theories. J Virol 2007; 81:5429-5436.
20. Tamerius J, Nelson MI, Zhou SZ, Viboud C, Miller MA, Alonso WJ. Global influenza seasonality: reconciling patterns across temperate and tropical regions. Environ Health Perspect 2011; 119:439-445.
21. Kenah E, Chao DL, Matrajt L, Halloran ME, Longini IM Jr. The global transmission and control of influenza. PLoS ONE 2011; 6:e19515. Available from: http://dx.doi.org/10.1371%2Fjournal.pone.0019515.
22. F Hoffmann-La Roche Ltd. Media release: Roche announces further progress in Tamiflu production expansion; 2005. http://www.roche.com/med-cor-2005-11-07, accessed on October 4, 2010.
23. Kramarz P, Monnet D, Nicoll A, Yilmaz C, Ciancio B. Use of oseltamivir in 12 European countries between 2002 and 2007-lack of association with the appearance of oseltamivir-resistant influenza A(H1N1) viruses. Euro Surveill 2009; 14:19112.
24. Simonsen L, Viboud C, Grenfell BT et al. The genesis and spread of reassortment human influenza A/H3N2 viruses conferring adamantane resistance. Mol Biol Evol 2007; 24:1811-1820.
25. Zaraket H, Saito R, Suzuki Y et al. Genetic makeup of amantadine-resistant and oseltamivir-resistant human influenza A/H1N1 viruses. J Clin Microbiol 2010; 48:1085-1092.
26. Niman HL. Emergence and fixing of antiviral resistance in influenza A via recombination and hitch hiking. Nature Precedings. 2009; Available at http://hdl.handle.net/10101/npre.2009.2832.1.
27. Plotkin JB, Dushoff J, Levin SA. Hemagglutinin sequence clusters and the antigenic evolution of influenza A virus. Proc Natl Acad Sci USA 2002; 99:6263-6268.
28. Smith DJ, Lapedes AS, de Jong JC et al. Mapping the antigenic and genetic evolution of influenza virus. Science 2004; 305:371-376.
29. Nelson MI, Simonsen L, Viboud C, Miller MA, Holmes EC. Phylogenetic analysis reveals the global migration of seasonal influenza A viruses. PLoS Pathog 2007; 3:1220-1228.
30. Meijer A, Lackenby A, Hungnes O et al. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007-08 season. Emerg Infect Dis 2009; 15:552-560.
31. Khan K, Arino J, Hu W et al. Spread of a novel influenza A (H1N1) virus via global airline transportation. N Engl J Med 2009; 361:212-214.
32. Fraser C, Donnelly CA, Cauchemez S et al. Pandemic potential of a strain of influenza A (H1N1): early findings. Science 2009; 324:1557-1561.
33. Rvachev LA, Longini IM Jr. A mathematical model for the global spread of influenza. Math Biosci 1985; 75:3-22.
34. Hufnagel L, Brockmann D, Geisel T. Forecast and control of epidemics in a globalized world. Proc Natl Acad Sci USA 2004; 101:15124-15129.
35. Balcan D, Colizza V, Gonçalves B, Hu H, Ramasco JJ, Vespignani A. Multiscale mobility networks and the spatial spreading of infectious diseases. Proc Natl Acad Sci USA 2009; 106:21484-21489.
36. Russell CA, Jones TC, Barr IG et al. The global circulation of seasonal influenza A (H3N2) viruses. Science 2008; 320:340-346.
37. Rambaut A, Pybus OG, Nelson MI, Viboud C, Taubenberger JK, Holmes EC. The genomic and epidemiological dynamics of human influenza A virus. Nature 2008; 453:615-619.
38. Bedford T, Cobey S, Beerli P, Pascual M. Global migration dynamics underlie evolution and persistence of human influenza A (H3N2). PLoS Pathog 2010; 6:e1000918. Available from: http://dx.doi.org/10.1371%2Fjournal.ppat.1000918.
39. Bahl J, Nelson MI, Chan KH et al. Temporally structured metapopulation dynamics and persistence of influenza A H3N2 virus in humans. Proc Natl Acad Sci USA 2011; 108:19359-19364.